Literature DB >> 8799184

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

M Laruelle1, A Abi-Dargham, C H van Dyck, R Gil, C D D'Souza, J Erdos, E McCance, W Rosenblatt, C Fingado, S S Zoghbi, R M Baldwin, J P Seibyl, J H Krystal, D S Charney, R B Innis.   

Abstract

The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic transmission is associated with this illness, but direct observation of abnormalities of dopamine function in schizophrenia has remained elusive. We used a newly developed single photon emission computerized tomography method to measure amphetamine-induced dopamine release in the striatum of fifteen patients with schizophrenia and fifteen healthy controls. Amphetamine-induced dopamine release was estimated by the amphetamine-induced reduction in dopamine D2 receptor availability, measured as the binding potential of the specific D2 receptor radiotracer [123I] (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl]benzamide ([123I]IBZM). The amphetamine-induced decrease in [123I]IBZM binding potential was significantly greater in the schizophrenic group (-19.5 +/- 4.1%) compared with the control group (-7.6 +/- 2.1%). In the schizophrenic group, elevated amphetamine effect on [123I]IBZM binding potential was associated with emergence or worsening of positive psychotic symptoms. This result suggests that psychotic symptoms elicited in this experimental setting in schizophrenic patients are associated with exaggerated stimulation of dopaminergic transmission. Such an observation would be compatible with an abnormal responsiveness of dopaminergic neurons in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799184      PMCID: PMC38625          DOI: 10.1073/pnas.93.17.9235

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices.

Authors:  N J Uretsky; S R Snodgrass
Journal:  J Pharmacol Exp Ther       Date:  1977-09       Impact factor: 4.030

2.  Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo.

Authors:  A L Green; M A el Hait
Journal:  J Pharm Pharmacol       Date:  1978-04       Impact factor: 3.765

3.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

5.  Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder.

Authors:  A J Cross; T J Crow; I N Ferrier; E C Johnstone; R M McCreadie; F Owen; D G Owens; M Poulter
Journal:  J Neural Transm Suppl       Date:  1983

6.  Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors.

Authors:  C Köhler; K Fuxe; S B Ross
Journal:  Eur J Pharmacol       Date:  1981-07-10       Impact factor: 4.432

7.  Provocative tests with psychostimulant drugs in schizophrenia.

Authors:  J A Lieberman; J M Kane; J Alvir
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism.

Authors:  J F van der Werf; J B Sebens; W Vaalburg; J Korf
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

9.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

Authors:  D F Wong; H N Wagner; L E Tune; R F Dannals; G D Pearlson; J M Links; C A Tamminga; E P Broussolle; H T Ravert; A A Wilson; J K Toung; J Malat; J A Williams; L A O'Tuama; S H Snyder; M J Kuhar; A Gjedde
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  The relationship between the stimulation of dopamine synthesis and release produced by amphetamine and high potassium in striatal slices.

Authors:  R D Schwarz; N J Uretsky; J R Bianchine
Journal:  J Neurochem       Date:  1980-11       Impact factor: 5.372

View more
  333 in total

1.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 3.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 4.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

Review 5.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 6.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

7.  Habit and skill learning in schizophrenia: evidence of normal striatal processing with abnormal cortical input.

Authors:  Thomas W Weickert; Alejandro Terrazas; Llewellyn B Bigelow; James D Malley; Thomas Hyde; Michael F Egan; Daniel R Weinberger; Terry E Goldberg
Journal:  Learn Mem       Date:  2002 Nov-Dec       Impact factor: 2.460

8.  Developmental markers of psychiatric disorders as identified by sensorimotor gating.

Authors:  Susan B. Powell; Mark A. Geyer
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

9.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

Review 10.  What is the mechanism whereby cannabis use increases risk of psychosis?

Authors:  Sonija Luzi; Paul D Morrison; John Powell; Marta di Forti; Robin M Murray
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.